BioSpace News Archive

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced it has completed the acquisition of TriMed, Inc., a global developer of solutions for the orthopedic treatment of lower extremities and upper extremities.

ADC Therapeutics SA announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA® in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.

ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, announced that company management will participate in three upcoming investor conferences.

Medicenna Therapeutics Corp. announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.

Flamingo Therapeutics announced its participation in the following upcoming investor and industry conferences.

UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for BIMZELX®, an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa.

Gennao Bio has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5 – 10, 2024 in San Diego, CA.

Curis, Inc. today announced that James Dentzer , President and Chief Executive Officer of Curis, will participate at the 23rd Annual Needham Virtual Healthcare Conference being held on April 8 - 11, 2024.

Ovid Therapeutics Inc. today announced that management will participate in a virtual presentation at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 9:30 a.m. ET.